Legato Capital Management LLC Makes New $482,000 Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Legato Capital Management LLC purchased a new position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 142,164 shares of the company’s stock, valued at approximately $482,000. Legato Capital Management LLC owned approximately 0.10% of Xeris Biopharma as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Barclays PLC increased its position in Xeris Biopharma by 87.8% in the third quarter. Barclays PLC now owns 324,472 shares of the company’s stock worth $925,000 after buying an additional 151,685 shares in the last quarter. Geode Capital Management LLC increased its position in Xeris Biopharma by 2.9% in the third quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company’s stock worth $9,502,000 after buying an additional 93,091 shares in the last quarter. Principal Financial Group Inc. increased its position in Xeris Biopharma by 30.3% in the third quarter. Principal Financial Group Inc. now owns 102,469 shares of the company’s stock worth $292,000 after buying an additional 23,843 shares in the last quarter. Quantbot Technologies LP purchased a new stake in Xeris Biopharma in the third quarter worth about $44,000. Finally, SG Americas Securities LLC increased its position in Xeris Biopharma by 188.5% in the third quarter. SG Americas Securities LLC now owns 60,202 shares of the company’s stock worth $172,000 after buying an additional 39,335 shares in the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Analyst Ratings Changes

XERS has been the subject of a number of analyst reports. HC Wainwright upped their price target on Xeris Biopharma from $6.00 to $6.60 and gave the stock a “buy” rating in a research report on Monday, November 11th. Piper Sandler cut Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 target price for the company. in a research report on Monday, November 11th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th.

Xeris Biopharma Trading Down 0.3 %

NASDAQ:XERS opened at $3.59 on Friday. Xeris Biopharma Holdings, Inc. has a 12-month low of $1.69 and a 12-month high of $3.87. The stock has a 50-day moving average price of $3.45 and a 200 day moving average price of $3.11. The stock has a market capitalization of $535.20 million, a P/E ratio of -7.98 and a beta of 2.61.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.